Research funder · Australia
Therapeutic Innovation Australia
- Grants since 2016
- 310
- Awarded, last 5 years (where amounts are published)
- —
- Funded works, last 5 years
- 146
- Funded works, all time
- 282
Grants
2026
Novel therapy for cancer
2026
Automated aseptic manufacture of serum eye drops for patients suffering dry eye conditions
2026
Development of a novel drug targeting age-related diseases
2026
A specific inhibitor of SLC7A11 (XCT) for single agent or combination treatment of cancers with mutant p53
2026
Therapeutic antibody discovery to block neurotrophin receptor cleavage
2026
A broad-spectrum antiviral target and anticancer target
2026
Development of human CLEC9A antibodies as cancer vaccines
2026
Enhanced skin delivery of vaccines by manipulating surface interactions on High Density Micro Array Patches (HD-MAP’s).
2026
Developing a GMP Compliant Manufacturing Process for Sight Lens, a cultured Limbal Epithelial Stem Cell Device
2026
Improving outcomes for breast cancer patients receiving CDK4/6 inhibitors
2026
Drug discovery for bacterial glycosyltransferases to combat AMR using the Monash Fragment Platform (MFP) screening facility
2026
A high-throughput screening campaign to find inhibitors of intracellular multi-drug resistant Staphylococcus aureus
2026
Advanced development of therapeutics against bacterial pathogens of biowarfare concern
2026
Potent and selective non-hallucinogenic serotonin 2A receptor agonists for the treatment of severe mental health disorders
2026
Targeting Sphingosine Kinase 1 for the Treatment of Pulmonary Hypertension
2026
Optimisation of a novel small molecule inhibitor for the treatment of lung cancer
2026
Manufacturability assessment of a whole parasite malaria vaccine
2026
Developing an ‘allogeneic stem cell-derived photoreceptor cell product’ compatible with good manufacturing practice (GMP) conditions.
2026
Fragment screen for E3 ligase inhibitors
2026
Optimisation of AAK1 gene knockdown for treatment of chronic pain
2026
Characterisation of covalent binders for a potential new drug target in oncology, Carbonic Anhydrase 3
2026
Development of an engineered thermal shift assay for the high-throughput discovery of integral membrane protein lead compounds
2026
Novel Small Molecule FIH Inhibitors for Treatment of Metabolic Disease
2026
Enhancing CAR-T cell therapy with mRNA vaccination
2026
Building a better leukaemia – Modeling paediatric acute myeloid leukaemia in pluripotent stem cells
2026
Development of novel anti-inflammatory biologics
2026
The establishment of a repository of in vitro-expanded cytomegalovirus-specific T cells for the treatment of glioblastoma multiforme
2026
Making bacteriophage therapy a reality: Implementation of a novel treatment pipeline to treat antimicrobial-resistant infections.
2026
Identifying Epigenetic Drivers of Drug Resistant Melanoma
2026
Development of biased agonists for schizophrenia
2026
Innovative Molecules for Imaging Neuroinflammation
2026
IRAP inhibitor lead optimisation
2026
Screening for a manufacturable antibody variant for PET-CT imaging of ovarian cancer
2026
Development of a high-throughput screening assay for a novel activated kinase ALPK1
2026
Multiplexed Evaluation of Splice‑Site Selectivity for RNA‑Targeted Therapeutics
2026
Inhibiting the Fanconi Anaemia pathway to target BRCA1/2 negative breast and ovarian cancers
2026
High Throughput Screening of Compound Libraries against a Novel Cancer Metabolism Drug Target
2026
mRNA vaccine for HCV
2026
Next-generation CRISPR therapeutics for autosomal dominant retinitis pigmentosa
2026